Heidi Hagen Joins Aastrom Board of Directors

By: Benzinga
Aastrom Biosciences (Nasdaq: ASTM ), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that Heidi Hagen has joined the Aastrom Board of Directors. Ms. Hagen is global chief operating officer at Sotio LLC, a biotechnology company developing new therapies for
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.